AUT00063 clinical trials
Also written AUT00063.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses AUT00063 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2014 (1)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Autifony Therapeutics Limited (3)
Studies
Open first, then newest update. How each study uses AUT00063 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing LossCompletedPhase 2Autifony Therapeutics LimitedNCT02345031Written as AUT00063
- Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire)CompletedPhase 2Autifony Therapeutics LimitedNCT02832128Written as AUT00063
- Evaluating Possible Improvement in Tinnitus Severity After 28 Days Dosing of the Study Drug AUT00063 Compared to PlaceboCompletedPhase 2Autifony Therapeutics LimitedNCT02315508Written as AUT00063